Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1G93A mouse model of ALS by Clark, RM et al.
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Interneurons play a crucial role in balancing neuronal activity in the brain1. In the devastating neurodegenerative 
disease amyotrophic lateral sclerosis (ALS), the loss of inhibitory interneuronal activity has been associated with 
the development of cortical hyperexcitability, linked to the onset of motor neuron degeneration that characterises 
the disease (for reviewed in2–4). Present in both sporadic and familial forms of ALS5–10, inhibitory dysfunction 
manifests in the motor cortex as reduced short-interval intracortical inhibition (SICI), which in combination 
with increased glutamate activity, is thought to cause cortical hyperexcitability11,12. This pathophysiological phe-
nomenon is identified in the motor cortex of patients prior to lower motor neuron dysfunction13; suggesting early 
changes in the balance between excitation and inhibition in the cortex may initiate, or in the very least, exacer-
bate, ALS pathology.
As a determinant of disease progression, clinical studies show that sporadic patients with greater intracortical 
inhibitory dysfunction have a more rapid clinical decline and shorter disease duration14. Similarly, familial SOD1 
mutation carriers with preserved intracortical inhibitory circuitry have a slower disease progression15, surviving 
an average of 13 years compared to 3 in sporadic patients16,17. This indicates that for both sporadic and familial 
ALS, the preservation, or restoration, of inhibition could be a promising neuro-protective strategy. However, little 
is known about the underlying architecture that may be initiating inhibitory dysfunction in the cortex, particu-
larly the cellular components involved.
Within the cortex, inhibition and the regulation of excitability is provided by a group of heterogeneous cells, 
the interneurons18,19, which have the potential to underlie inhibitory dysfunction in the ALS cortex. It is known 
that essential components of the inhibitory system are altered in ALS. The main inhibitory neurotransmitter, 
γ -aminobutyric acid (GABA) is reduced in the motor cortex of ALS patients20, mRNA levels of the prominent 
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GABAA receptor subunit alpha-1 are reduced21 and pet scans reveal reduced binding of the GABA receptor 
ligand, flumazenil, in the motor cortex of sporadic ALS patients22. Furthermore, the reduced SICI observed in 
patients is thought to reflect changes in the function of inhibitory GABA-secreting cortical interneurons, as well 
as the circuits they contribute to11,12. The pathological consequence of this is demonstrated by the concurrent 
loss of GABAergic activity in the motor cortex, alongside elevated levels of glutamate23, which is proposed to 
cause motor neuron degeneration through the trans-synaptic anterograde propagation of glutamate toxicity13,24. 
However, despite increasing evidence that interneurons are likely of central importance in ALS pathophysiology, 
it is poorly understood which types of interneurons are involved, and therefore, how specific interneuronal net-
works are implicated in disease.
To address these questions, this study aimed to determine the extent and timing of interneuron pathology in 
the cortex of the SOD1G93A mouse model of ALS25. This mouse model develops prominent motor symptoms, has 
a well documented history of disease progression26, and was recently used to identify early cortical motor dys-
function27, including increased excitability of layer V pyramidal neurons in the motor cortex28, which preceded 
lower motor neuron symptoms29 and degeneration of cortico-spinal motor neuron pathways30. However, the 
potential for an underlying interneuronal phenotype has not yet been fully explored in this ALS model. Therefore, 
using immunohistochemistry and cell tracing software, we investigated if there was a region-dependent vul-
nerability of specific interneuron populations in the cortex of the SOD1G93A mouse. We report a substantial 
loss of CR-expressing interneurons, specifically in the SOD1G93A motor cortex, with differential vulnerability of 
NPY-expressing interneurons at late-disease stages, potentially reflecting compensatory mechanisms. In addition, 
the early symptomatic involvement of both CR- and NPY-interneurons is demonstrated, supporting an early 
and progressive contribution of inhibitory circuits throughout disease. Collectively, this data suggests NPY- and 
CR-interneurons are involved in a motor-specific inhibitory phenotype from early stages in disease – thereby 
demonstrating the potential for an underlying inhibitory contribution in the SOD1 mouse model of ALS.
Results
Ǧͷ
Ǥ Within the cortex, inhibitory microcircuits are comprised of a wide variety of interneuron 
populations that target specific neuronal domains to facilitate the fine-tuning of cortical neuronal activity. These 
cell types are arranged in well-ordered wiring patterns that maintain the complex functions of cortical regions 
by their unique placement, connections and firing properties1. Changes in specific interneuron populations are 
therefore likely to affect synaptic transmission in the motor cortex and compromise the regulation of network 
excitability, including motor output from layer V corticomotoneurons. To determine if specific interneuron pop-
ulations were altered in the SOD1 cortex, we used immunohistochemistry to assess the potential changes in 
the numbers of interneuron populations in the motor and somatosensory cortex of late-symptomatic (20 week) 
SOD1 mice, and in age and litter-matched wild type (WT) controls. We quantified interneuron density (cells per 
mm2) in both the supragranular and infragranular lamina of motor (Ms, Mi) and somatosensory cortices (Ss, 
Si) to determine if cell position in cortical regions influenced pathology (Fig. 1a–c). GABAergic interneuron 
subtypes were differentiated according to the selective expression of calcium binding proteins [calbindin (CB), 
calretinin (CR), parvalbumin (PV)] and neuropeptides [neuropeptide Y (NPY), somatostatin (SOM), vasoactive 
intestinal peptide (VIP)]19 (Fig. 2a–f). We found that of the interneuron populations expressing calcium-binding 
proteins, the density of CR-expressing neurons was significantly decreased in the supragranular lamina of the 
motor cortex (layers I-IV) (Fig. 2g,h). In this region, CR-neurons were reduced by up to 37% of WT controls 
(55 ± 6 p/mm2 WT Ms, 35 ± 6 p/mm2 SOD1G93A Ms) (P < 0.05, two-way ANOVA, Bonferroni post-hoc) (Fig. 2j), 
while the density of this population remained unaltered in the infragranular motor cortex (32 ± 5 p/mm2 WT Mi, 
19 ± 1.9 p/mm2 SOD1G93A Mi), and unaltered in both lamina of the somatosensory cortex (43 ± 6 p/mm2 WT Ss, 
44 ± 4 p/mm2 SOD1G93A Ss; 12 ± 1 p/mm2 WT Si, 10 ± 1 p/mm2 SOD1G93A Si). No significant differences were 
detected in either of the other calcium binding populations, CB- or PV-expressing neurons in SOD1G93A mice 
and WT controls (Fig. 2i,k). In direct contrast, the number of NPY-expressing neurons was significantly increased 
by 29% in the supragranular motor cortex (41 ± 1 p/mm2 WT Ms, 54 ± 2 p/mm2 SOD1G93A Ms) and by 30% 
in the infragranular motor cortex of SOD1G93A mice compared with WT (35 ± 1 p/mm2 WT Mi, 46 ± 2 p/mm2 
SOD1G93A Mi) (P < 0.05, two-way ANOVA, Bonferroni post-hoc) (Fig. 2l), an unexpected finding. In the soma-
tosensory cortex NPY-neurons remained unchanged in both lamina (45 ± 2 p/mm2 WT Ss, 48 ± 3 p/mm2 
SOD1G93A Ss; 29 ± 1 p/mm2 WT Si, 32 ± 1 p/mm2 SOD1G93A Si). Analysis of other neuropeptide expressing pop-
ulations, SOM- and VIP-expressing neurons, identified no further differences in motor or somatosensory lamina 
compared to WT (Fig. 2m,n). These investigations demonstrate that at end-stage in the SOD1G93A cortex, at a time 
of established cortical vulnerability in this ALS model30, distinct regions of the motor cortex undergo selective 
alteration involving the differential vulnerability of neurons expressing CR and NPY.
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Ϳ͹ 
Ǥ The early alteration of interneuron populations in the motor cortex could initiate a cas-
cade of events resulting in an inability to maintain excitability in the cortex. In the TDP-43 model of ALS, 
SOM-expressing interneurons has been shown to initiate hyperexcitability in the motor cortex at an early dis-
ease stage31. We therefore examined the density of CR- and NPY-expressing populations at earlier stages in the 
SOD1G93A disease course: 8 weeks (from the earliest signs of symptoms in this model), 12 weeks and 16 weeks26 
(Fig. 3a). The mean density of CR-expressing neurons was decreased by 31% from (16 weeks) in the supragran-
ular motor cortex of SOD1G93A mice compared with WT (88 ± 13 p/mm2 WT Ms, 60 ± 8 p/mm2 SOD1G93A Ms) 
(P < 0.05, two-way ANOVA, Bonferroni post-hoc) (Fig. 3b). This decrease was not significant in the infragran-
ular lamina of the motor cortex (61 ± 8 p/mm2 WT Ms, 46 ± 6 p/mm2 SOD1G93A Ms), and was not present in the 
somatosensory cortex (71 ± 12 p/mm2 WT Ss, 48 ± 11 p/mm2 SOD1G93A Ss; 21 ± 9 p/mm2 WT Si, 17 ± 2 p/mm2 
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SOD1G93A Si). The density of CR-expressing neurons remained unchanged relative to controls at earlier time 
points in the SOD1G93A cortex at 8 and 12 weeks. This suggests either a loss of CR-expressing neurons, or a 
potential reduction in the expression levels of CR in this distinct interneuron population, occurs during the later 
symptomatic phase in this model and is restricted to the upper layers of the motor cortex.
Interestingly, in contrast to the end-stage increase in NPY-expressing neurons in the SOD1G93A motor cor-
tex (Fig. 2d), from symptom onset (8 weeks) NPY-neurons were significantly decreased by 17%, but only in 
the supragranular lamina of the SOD1G93A motor cortex (55 ± 1 p/mm2 WT Ms, 45 ± 2 p/mm2 SOD1G93A Ms) 
(P < 0.05, two-way ANOVA, Bonferroni post-hoc) (Fig. 4a,b). At the same time point NPY-neurons remained 
unaltered in the infragranular lamina of the motor cortex (39.5 ± 3 p/mm2 WT Ms, 38 ± 2 p/mm2 SOD1G93A Ms), 
and in other somatosensory regions (49 ± 2 p/mm2 WT Ss, 53 ± 2 p/mm2 SOD1G93A Ss; 33 ± 2 p/mm2 WT Si, 
31 ± 2 p/mm2 SOD1G93A Si). Notably, NPY-expressing neurons were also unaltered in all cortical regions inves-
tigated at 12 and 16 weeks. These data suggest that changes to interneurons can occur early in the SOD1G93A 
motor cortex, is progressive with CR-expressing neurons, and may alter over the disease course in relation to 
NPY-expressing neurons.
Ǧͷ
Ϳ͹ motor 
Ǥ A characteristic hallmark of neuronal degeneration is the alteration of neurite structure, which 
can precede overt changes in cell number, while augmenting connectivity patterns and the innervation field 
of neuronal populations32–36. Due to the progressive nature of CR-cell alterations, we investigated whether 
CR-expressing neurons were abnormal in SOD1G93A mice by examining branching patterns in 40um coronal sec-
tions at two contrasting disease stages: an early symptomatic time point (8 weeks), prior to loss of CR-expressing 
Figure 1. Representative images of sections used for quantitative analysis in WT and SOD1G93A mice. 
Coronal sections, each 40 μ m thick, from bregma 1.18 to − 0.58 were used for quantitative analysis at four stages 
of disease progression in each cohort of mice. (a) An example section used in the study (Interaural 4.06 mm, 
Bregma 0.26 mm) with primary motor (M1) and secondary somatosensory (S2) regions denoted by dotted 
lines. Arrows indicate anatomical landmarks used to identify regions of interest, as visualised by DAPI staining: 
namely, the namely the third (3 V) and lateral ventricles (LV), shape and appearance of the corpus callosum 
(cc) and anterior commissure (aca). (b) The motor cortex imaging site as validated in the Thy1-eYFP-H mouse, 
which has particularly prominent yellow fluorescent protein expression in large layer V corticospinal neurons 
(green) within the motor cortex57,80. (c) A representative image of a calretinin (green), Nissl (red), DAPI 
(blue) cortical coronal section used for analyses. In each section, the motor (i) and somatosensory (ii) regions 
of interest (boxed areas enlarged to the right) were used for quantitative analyses, with cortical layers I–VI 
visualised by Nissl staining (iii).
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Figure 2. Calretinin and Neuropeptide Y interneuron subtypes are differentially altered in specific 
lamina of the SOD1G93A motor cortex. (a–f) Calcium binding proteins and neuropeptides (green) were used 
to visualise specific interneuron populations in the cortex, showing labelling patterns of calbindin (CB; a) 
calretinin (CR; b) parvalbumin (PV; c) and neuropeptide Y (NPY; d) somatostatin (SOM; e) and vasoactive 
intestinal peptide (VIP; f) populations in 20 week WT cortex stained with DAPI (blue) and Nissl (red). The 
boxed areas (a–f) in the high magnification images show co-localisation of interneuron labels with Nissl 
stain. (g,h) At 20 weeks, analysis of motor cortex, reveals the normal distribution of CR-interneurons in WT 
motor cortex (g) but a striking reduction in particular in layers I-IV of SOD1G93A motor cortex. (h) Analysis 
of immunopositive neurons within the SOD1G93A motor (M) and somatosensory (S) cortex showed that the 
density of calretinin-expressing interneurons was significantly decreased specifically within the supragranular 
(Ms, layers I-IV) lamina of the motor cortex (j) and the density of Neuropeptide Y-expressing interneurons 
was significantly increased in both the supragranular (Ms, layers I-IV) and infragranular lamina (Mi, layers 
V-VI) of the motor cortex. (l) No other interneuron populations were significantly altered in either motor 
or somatosensory cortex. (i,k,m,n) Values in graphs represent means ± SEM. *P < 0.05, two-way ANOVA, 
Bonferonni’s multiple-comparison test with n = 6 mice per group. Scale bar in (a–f) 20 μ m, (g–h) 100 μ m.
www.nature.com/scientificreports/
5SCIENTIFIC REPORTSȁͽǣͺͺͺͼͷȁǣͷͶǤͷͶ͹;Ȁͺͺͺͼͷ
neurons demonstrated at 16 weeks, and an end-stage time point, when CR-neuron loss has been established for 
a prolonged period in the SOD1G93A disease course. Immunolabeling of the supragranular lamina of the motor 
cortex revealed extensive differences between CR-labelled neurites from end-stage (20 week) SOD1G93A mice and 
Figure 3. Calretinin-expressing interneurons are progressively lost during the symptomatic phase in the 
SOD1G93A motor cortex. (a) CR-expressing neurons were labelled throughout the SOD1G93A disease course, 
showing neurons were present at comparable levels in SOD1G93A and WT mice at 8 weeks (early symptom 
onset) and 12 weeks in motor (M) and somatosensory cortex (S). (b) Analysis of 16 week symptomatic 
SOD1G93A mice showed that CR neurons were significantly decreased in the supragranular lamina of motor 
cortex (Ms, layers I-IV) compared to WT mice. CR-neurons were progressively reduced in the supragranular 
lamina of motor cortex (Ms, layers I-IV) in 20 week end-stage SOD1G93A mice (arrow heads in a). Values in 
graphs represent means ± SEM. *P < 0.05, two-way ANOVA, Bonferonni’s multiple-comparison test with n = 6 
mice per group. Scale bar in (a) 50 μ m.
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Figure 4. Neuropeptide Y populations are differentially altered from early symptom onset in the SOD1G93A 
motor cortex. (a) NPY-expressing neurons were labelled at different stages in the SOD1G93A disease course: 
8 weeks (early symptom onset), 12 weeks,16 weeks and 20 weeks (end-stage). (b) The mean density of NPY-
expressing neurons was significantly decreased in the supragranular lamina of the motor cortex (Ms, layers 
I-IV) in early symptomatic (8 week) SOD1G93A mice compared to WT (arrow heads in a). NPY-expressing 
neurons were present at comparable levels in SOD1G93A and WT mice at 12 weeks and 16 weeks, with a late 
increase in cell density detected throughout the motor cortex at 20 weeks in end-stage SOD1G93A mice (arrow 
heads in a). The somatosensory cortex showed no change in NPY-expressing neurons at any stage of disease in 
supragranular (Ss, layers I-IV) or infragranular lamina (Si, layers V-VI) in SOD1G93A and WT mice. Values in 
graphs represent means ± SEM. *P < 0.05, two-way ANOVA, Bonferonni’s multiple-comparison test with n = 6 
mice per group. Scale bar in (a) 100 μ m.
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WT controls. CR-neurons in WT tissue had well-developed and extensive neurite trees, whereas the same neu-
rons in SOD1G93A tissue exhibited a substantial reduction in neurite labelling (Fig. 5b). Quantification confirmed 
this observation, revealing a significant reduction in the proportion of CR-positive neurons with primary (~70%), 
secondary (~25%) and tertiary (~14%) order processes in the SOD1G93A cortex compared with WT (Fig. 5d). 
This was accompanied by a nine-fold increase in the proportion of SOD1G93A CR-neurons with no neurites vis-
ible (Fig. 5d). Likewise, the average length of tertiary order processes (~48%) (Fig. 5f) and the average area of 
primary (~75%), secondary (~79%) and tertiary (~75%) order processes (Fig. 5h) was significantly decreased in 
the SOD1G93A motor cortex compared to WT. Overall group comparisons revealed that the SOD1G93A genotype 
significantly reduced the average length (~38%) and volume (~78%) of all CR-labelled neurites, independent of 
branch order (Fig. 5f,h). These results demonstrate that at end-stage the remaining population of CR-expressing 
neurons are irregular with reduced distribution of CR-immunoreactivity in their processes, which may translate 
into abnormal function in the motor cortex.
We next evaluated the CR-labelling patterns in the early symptomatic tissue (at 8 weeks) to establish if altera-
tions were present prior to loss of CR-expressing neurons. Cell tracing revealed a similar, although more subtle, 
pattern of alterations to SOD1G93A CR-neurons at this time point (Fig. 5a). There was a significant reduction in 
the proportion of CR-neurons with primary neurites (~5%) and a small increase in neurons with no processes 
visible (Fig. 5c). However, there was a trend towards a two-fold increase in the average length and area of neurites 
of CR-neurons in SOD1G93A tissue, which was only significant in quaternary order processes (Fig. 5e,g). These 
results strongly suggest a potential involvement of CR-networks in relation to motor neuron circuitry defects 
previously observed in the motor cortex.
Discussion
ALS is a system degeneration disorder characterised by the selective loss of both upper (corticospinal) and lower 
(spinal) motor neurons37. While lower motor neuron dysfunction and loss has been well characterised in animal 
models of ALS25,29,38,39, it is only in recent years that the potential contribution of cortical pathology has begun 
to be investigated27,40. Recent studies show that corticospinal motor neurons mirror some of the earliest signs of 
degeneration that occur in lower motor neurons41, including early electrophysiological changes, dendritic regres-
sion and cell loss42–44. Additionally, dysfunctional astrocytes, microglia and oligodendrocytes have been shown 
to contribute to disease progression and motor neuron degeneration in SOD1 mice45–50, increasing interest in the 
role of cortical neuronal and non-neuronal populations in these models46,51. Indeed, with the recent detection 
of early hyperexcitability in the motor cortex of patients, these and other studies support a cortical origin of 
disease4,6,9, initiated by cortical dysfunction, subsequently spreading to spinal motor neurons6,52. As such, there 
is increasing interest in the cortical components that may regulate motoneuronal circuitry, including the diverse 
cortical interneuron populations that underpin extrinsic regulation of excitability in the cortex3,53. Therefore, we 
investigated interneuron populations over a time course to establish potential involvement in the disease. The 
interneuron pathology reported here strongly support a sequence of inhibitory alteration, which is restricted to 
the motor cortex, includes specific interneuron populations in the SOD1 mouse model, and begins early in dis-
ease at a stage when, according to previous reports, corticospinal motor neurons are altered30.
Changes in CR- and NPY-expressing interneuron populations are evident from 8 weeks in the supragranular 
lamina of the motor cortex, progress to loss of CR-expressing neurons by 16 weeks, and include contrasting alter-
ation of CR and NPY populations by end-stage disease at 20 weeks. The early involvement of both populations 
within the supragranular motor cortex indicates inhibitory cell deficits originate in the upper cortical layers (I-IV) 
of the motor cortex in the SOD1 mouse model. We found a significant increase in the length of the most distal, 
terminal CR-processes from 8 weeks, a number of weeks prior to their apparent loss at 16 weeks, and preceding 
the marked decrease in process complexity by end-stage. While we have not identified the cause of this unique 
regional susceptibility, it likely involves the layer II/III inhibitory and excitatory populations, and corticospinal 
motor neuron apical processes.
The majority of CR-interneurons reside within layer II/III, where they may directly synapse with apical pro-
cesses from layer V corticospinal motor neurons and provide feedback or lateral inhibition54. In SOD1G93A mice, 
it has been shown that at 8 weeks the apical dendrites of these layer V motor neurons located within layer II/III 
are severely degenerated and have reduced spine density, while the basal motor neuron dendrites in layer V do not 
exhibit overt signs of degeneration30. This may suggest unique regional involvement of CR-neurons is initiated by, 
or responding to, alterations in spine density of the apical corticospinal motor neuron dendrites within layer II/
III of the motor cortex. Therefore, the dendritic inhibition of pyramidal neurons may be less effective. In support 
of this, the apical dendritic spines of layer V projection neurons, typically receive excitatory inputs from thalam-
ocortical neurons and from local layer II/III neurons55, whereas basal spines preferentially receive inputs from 
distal sensory and motor nuclei56. Recent works suggest corticospinal motor neuron spine loss can occur at 3 
weeks in the SOD1G93A mouse model accompanied by increased functional excitatory synaptic activity onto layer 
V pyramidal neurons28. Hence mutant SOD1 may mediate increased excitability through early spine dynamics, 
leading to apical dendritic regression and inhibitory neuronal alteration; however, aberrant inhibition may also 
have the capacity to initiate pathology.
Close parallels can be drawn between pathology in the SOD1 mouse, and pathogenic mechanisms in the TDP-
43 and HERV-K mouse models of ALS. In TDP-43A315T mice there is a loss of dendritic spines on layer V projec-
tion neurons that has been shown to coincide with decreased excitability, preceding motor dysfunction and cell 
loss57–59. However, weeks prior to this decreased activity a population of somatostatin-expressing interneurons 
was found to be hyperactive, inhibiting parvalbumin interneurons that due to their direct connections with layer 
V neurons resulted in hyperexcitability of the layer V neurons31. Therefore, there is potential for early inhibitory 
alteration of specific cortical circuits to cause a switch in the excitable state of layer V neurons, leading to abnor-
mal spine dynamics and a decline in neuronal function. While we find interneuron pathology from symptom 
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Figure 5. Calretinin-expressing neurites undergo progressive alterations in branching complexity from 
symptom onset in the supragranular SOD1G93A motor cortex. (a–d) CR-labelled tissue sections were imaged 
and immunopositive neurons in the supragranular lamina assessed using cell tracing software to analyse neurite 
morphology (arrowheads, insets) at 8 weeks (a) and 20 weeks (b) in WT and SOD1G93A tissue. The division of 
the neurite structure into primary, secondary, tertiary and quaternary order processes (as observed with CR-
labelling) was used for all investigations. (c,d) A proportional analysis was conducted to determine the extent 
of CR-labelled processes remaining on neurons in the supragranular motor cortex at both time points, showing 
a significant increase in neurons with no, or fewer, CR-labelled processes visible in early symptomatic (8 week) 
SOD1G93A mice and in 20 week end-stage SOD1G93A mice compared to WT. (e–h) The mean branch length 
(e,f) and mean volume (g,h) of CR-labelled neurites were also assessed, demonstrating a pre-symptomatic 
increase in the length and volume of distal neurite processes in 8 week SOD1G93A mice (e,g). Analysis of 20 week 
end-stage SOD1G93A mice showed a significant reduction in the length and volume of CR-labelled processes 
compared to WT (f,h). Values in graphs represent means ± SEM. *P < 0.05, two-way ANOVA, Bonferonni’s 
multiple-comparison test with n = 6 mice per group. Scale bar in (b) 20 μ m.
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onset in this study, other works using the SOD1 zebra fish have identified interneuron functional deficits as the 
earliest pathophysiological event. This suggests that much like the TDP-43 model, there is potential for early 
involvement of inhibitory microcircuits to cause a pathological switch in the excitability of projection neurons 
within the SOD1 motor cortex. Similarly, mice that express the human endogenous retrovirus-K in neurons also 
display hyperexcitability of layer V neurons, and develop a progressive motor dysfunction that includes loss of 
both upper and lower motor neurons with distinct reductions in the dendritic length, branch number and spine 
density of cortical pyramidal neurons. As the activated HERV-K virus is found specifically within neurons of 
sporadic ALS patients, this may suggest pathogenic mechanisms can lead to the same phenotypic neurodegen-
erative disease through the misregulation, or aberrant activity, of layer V neurons. While it remains unclear why 
interneurons within the motor cortex are vulnerable to disease, it is likely that their involvement is central to a 
convergence of excitatory imbalance in the disease (reviewed in2,3).
Cortical interneurons are essential of the regulation of normal excitability, but it is increasingly appar-
ent that CR-interneurons in particular are susceptible to pathogenic changes in excitability. In this study the 
CR-expressing interneurons were reduced in number and showed morphological abnormalities. While we cannot 
conclude if this represents loss of the protein or loss of the cell, there were changes consistent with altered network 
activity. In mouse models of epilepsy and in the epileptic human hippocampus increased excitability is accom-
panied by the loss of CR-containing interneurons and reorganisation of their neurites60. This is exemplified in 
the sclerotic hippocampus where the density of CR-immunopositive neurons is significantly decreased, while in 
non-sclerotic hippocampus CR-interneurons are preserved61. Our finding that CR-interneurons can be found to 
have altered morphology as early as 8 weeks raises the possibility that they are involved in the initial alteration of 
the motor network in an excitable state. Although their functional impact on circuitry needs to be further investi-
gated, it has recently been shown that the formation of CR-interneurons innervation field is an activity dependent 
process, with the length of axonal arbours on both multipolar and bipolar populations influenced directly by 
alterations in excitability62. Furthermore, CR-interneurons are a unique inhibitory population in the cortical 
circuit, as they preferentially regulate the activity of other GABAergic inhibitory populations, and subsequently 
the actions of principal neurons via disinhibition63,64. In this manner, not only may CR-interneurons be more 
susceptible to early alterations in excitability, but they also have the ability to potentiate a wide reaching inhibitory 
and excitatory circuit dysfunction, due to their distinctive connectivity patterns and continual alteration through-
out disease. The major excitatory input to corticospinal motor neurons is a pathway from layer II/III to layer 
V65; hence interneurons located within layer II/III may disproportionately influence corticospinal motor neuron 
activity via disynaptic feedforward inhibition54. Indeed, the contrasting and somewhat unexpected involvement 
of NPY-interneurons may also support a continuum of pathogenic alterations triggered by altered excitability.
Neuropeptides are preferentially released during sustained neuronal stimulation66, and are thought to act as 
an endogenous neuroprotectant against increased pathogenic cortical activity67–70. Extensive literature from the 
epilepsy field supports a neuroprotective role for NPY as an endogenous anti-epileptic67. Mice lacking NPY are 
more susceptible to spontaneous and pharmacologically induced seizures, which can be reversed by intracerebral 
administration of NPY71,72. Moreover, increased synthesis and release of NPY has been reported following sei-
zure activity73,74 and increased numbers of interneurons expressing NPY following excitotoxin treatment75. This 
indicates increased NPY expression by interneuron populations may be an advantageous intrinsic mechanism 
to counteract increased activity of cortical excitatory neurons. Therefore, our finding of increased density of 
NPY-immunoreactive neurons at end-stage may be a direct consequence of increased activity in the motor cortex.
In line with this, it is quite interesting that NPY pathology was first restricted to the upper cortical layers of 
the motor cortex, where CR-populations are predominately altered, but by end-stage NPY pathology was wide-
spread throughout the entire motor cortex. This may suggest initial inhibitory deficits cause a localised change 
in excitability within the motor cortex, which spreads, resulting in increased NPY-immunoreactivity throughout 
the major excitatory pathways within the diseased motor cortex. In the context of our early results, this may 
suggest a late stage compensatory mechanism whereby NPY expression is upregulated to dampen the effects of 
altered excitability in motor circuitry. However, as we show a decreased density of NPY-interneurons at 8 weeks, 
excitability in the motor cortex may fluctuate throughout the disease course. In this respect, it is also interesting to 
note that both SOD1 and TDP-43 ALS models demonstrate the increasing involvement of neuropeptide systems, 
as somatostatin-interneuron numbers are reported to increase by late stages in TDP mice31. This is particularly 
important because it shows that not all interneuron populations may be involved in a similar manner in the dis-
ease, and the targeting of inhibitory populations for the restoration of normal excitability in the ALS cortex might 
best be considered in a subpopulation specific paradigm.
Conclusion
Our study clearly demonstrates a novel timeline of interneuron pathology in the SOD1G93A motor cortex. This 
pathology included the specific involvement of NPY- and CR-expressing interneuron populations. It is important 
to note we studied interneuron populations with immunohistochemistry; hence it remains to be determined how 
interneuron alterations functionally influence the disease, whether pathology is primary or secondary to excita-
bility, and protective or pathogenic in the context of the disease. Nonetheless, we have demonstrated that changes 
originate in the upper cortical layers of the motor cortex from early symptom onset, and progress to involve the 
entire motor cortex by end-stage disease. While the role of cortical components in motor neuron circuitry is only 
just beginning to be elucidated, it is apparent that specific inhibitory populations may have an underappreciated 
role in the disease. It will be important for future electrophysiological studies to determine if this continuum of 
interneuron alteration might compromise the cortical motor network and will be essential for developing effec-
tive therapeutics aimed at the restoration of normal excitability for the treatment and prevention of ALS.
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
Male transgenic mice carrying a high copy number of the human SOD1G93A mutation [strain 004435 
B6.Cg-Tg(SOD1G93A)1Gur.J - backcrossed for more than 10 generations on a C57BL/6 background] [Jackson 
Laboratory (CA, USA) (http://www.jax.org/strain/004435)], and their wild-type littermates were used for his-
tological analyses. Mice were genotyped and copy number determined (25 ± 2) using a multiplexed quantita-
tive polymerase chain reaction according to the Jackson Laboratory protocol: http://www.jax.org. Animals were 
housed in individually ventilated cages at 20 oC, on a 12 hour light-dark cycle, with access to food and water ad 
libitum. Presence of the SOD1G93A transgene was assessed according to standard protocols76. All procedures were 
approved by the Animal Ethics Committee of the University of Tasmania and conducted in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013.
Ǧͷ
Ϳ͹Ǥ SOD1G93A transgenic mice 
and age-matched wild-type controls were sacrificed from symptom onset in the SOD1G93A mouse27 and assessed 
at defined time points until end-stage in the disease course: 8 weeks (symptom-onset), 12 weeks, 16 weeks and 20 
weeks of age (end-stage). The final time point was determined as an ethical stage preceding the 157-day typical 
life span in this SOD1G93A mouse model26, and the earliest time point investigated when distal pathology has been 
previously described in our laboratory77. Mice were terminally anaesthetised (sodium pentobarbitone, 140 mg/kg, 
i.p) and transcardially perfused with 4% paraformaldehyde (PFA; w/v) [(in 0.01 M phosphate buffered saline 
(PBS)]. For each of the above time points, the cortex was obtained from six animals per genotype per time point. 
The brains were post-fixed in 4% PFA overnight at 4 oC, then stored at 4 oC in 0.01 M PBS containing 0.1% w/v 
sodium azide (Sigma Aldrich, Australia).
Ǥ The brain was cut at Bregma − 4.00 mm, and the anterior portion cryoprotected with 
increasing concentrations of sucrose (4%, 16%, 30%) dissolved in 0.01 M PBS. Serial coronal cryostat sections (40μ m) 
were generated using a Leica CM 1850 cryostat (Biosystems, Australia) and collected as free-floating sections into 
24 well plates (Corning Life Sciences, USA) containing sodium azide, kept in sequential order and stored at 4 oC 
until processed for immunohistochemistry.
ͷ
Ϳ͹Ǥ For analysis of cortical 
interneuron pathology, free-floating sections were processed using standard immunohistochemical methods57,78. 
Cortical interneurons were identified by the expression of calcium binding proteins: calbindin (CB), calretinin 
(CR) and parvalbumin (PV), or by neuropeptides: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP) 
and somatostatin (SOM)19. Every tenth serial sections (400 μ m apart) was incubated with antibodies recognizing 
cell-type specific interneuron markers diluted in 0.01 M PBS containing 0.3% Triton-X-100 (see Table 1 for anti-
body dilutions). Following washes (3 × 0.01 M PBS, 10 min) to remove excess unbound antibodies, sections were 
incubated with alexa-fluor conjugated secondary antibodies (1:1000, Thermo-Fisher Scientific, Australia) diluted 
in 0.01 M PBS at room temperature for 2hrs, followed by DAPI staining (4′ ,6-diamidino-2-phenylindole, 1/50000, 
Thermo-Fisher Scientific, Australia). After further washes (3 × 0.01 M PBS, 10 min), sections were mounted 
onto glass slides and coverslipped using fluorescent PermaFluor™ aqueous mounting medium (Thermo-Fisher 
Scientific Australia Pty Ltd, Australia). Specificity of all antibodies was verified by incubating sections with the 
corresponding secondary antibody without pre-incubation of primary antibody.
Ǥ Immunofluorescence was captured using a Zeiss LSM 510 
DuoScan confocal microscope (Carl Zeiss Microscopy, Germany), running Zen software (V3.2, 2008) equipped 
with Ar488 and HeNe543 lasers. Cell bodies were quantified blind to genotype in the supragranular (layers I-IV) 
and infragranular lamina (layers V-VI) of the primary motor and secondary somatosensory cortices, comparable 
coronal sections were selected from 1.18mm to − 0.58mm relative to bregma (Sections 21–36 according to the 
Antigen Description of Immunogen
Source, Host Species, Cat#, Clone or 
Lot#, RRID Concentration Used
Calbindin D-28k
Calcium-binding protein of the EF-
hand family related to calmodulin and 
troponin-C
Millipore, rabbit polyclonal, Cat#AB1778 
Lot# RRID:AB_2068336 1:1000 μ l (IHC)
Calretinin
Calcium-binding protein of the EF-hand 
family related to calbindin D-28k and 
calmodulin
Swant, mouse monoclonal, Cat#6B3 
Lot#010399 RRID:AB_1000330 1:1000 μ l (IHC)
Parvalbumin
Calcium-binding protein of the EF-
hand family related to calmodulin and 
troponin-C
Swant, mouse monoclonal, Cat#235 
Lot#10-11 (F) RRID:AB_10000343 1:1000 μ l (IHC)
Neuropeptide Y Neuropeptide Y conjugated to bovine thyroglobulin (BTg) with glutaraldehyde
Immunostar, rabbit polycloncal, 
Cat#22940 Lot#1112001 RRID:AB_572253 1:500 μ l (IHC)
Somatostatin
Synthetic peptide coupled to keyhole 
limpet hemocyanin (KLH) with 
carbodiimide (CDI) linker
Immunostar, rabbit polyclonal, Cat#20067 
Lot#216002 RRID:AB_572264 1:1000 μ l (IHC)
Vasoactive Intestinal Peptide
Porcine VIP coupled to bovine 
thyroglobulin (BTg) with carbodiimide 
(CDI) linker
Immunostar, rabbit polyclonal, Cat#20077 
Lot#1339001 RRID:AB_572270 1:1000 μ l (IHC)
Table 1. Primary Antibodies.
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Paxinos and Franklin Mouse Brain Atlas79 (Fig. 1). A plan-apochromat 20x objective (N.A. 0.8, Zeiss) was used to 
generate z-plane images with 2μ m intervals through 16 μ m of tissue depth. Primary motor and secondary soma-
tosensory cortices were identified by anatomical landmarks referring to the appearance of the lateral ventricles, 
the shape of the third ventricle and the appearance of the anterior commissure and corpus callosum, as visualized 
with DAPI staining and according to the Allen Mouse Brain Atlas (© Allen Institute for Brain Science: http://
mouse.brain-map.org) (Fig. 1). Immunopositive neurons (cells with positive labelling in cell soma) were counted 
using Image J software (National Institutes of Health, USA) with the integrated Cell Counter plugin utilising Nissl 
staining to identify cortical layers. To compare densities of immunopositive neurons in SOD1G93A and wild-type 
mice, all neurons within the regions of interest (ROI) were manually marked, counted and the density calculated 
using the area of the ROI (values are given in cells/mm2). The densities were then averaged across animals with 4 
sections per cortical region per mouse included in analyses.
Ǥ For analysis of neurite labelling patterns, 40 μ m coronal tissue sections were used 
to generate Z-stack images of neurons with 1 μ m intervals through 16 μ m of tissue depth within the motor cor-
tex. Neurons with full arbours within z-stack were analysed using the cell tracing software NeurolucidaTM (MBF 
Bioscience, USA) with the z-stack margins set to include one complete cell layer. For quantification of neurites 
immunoreactive for calretinin (CR), neurons were traced through stacks with processes marked, and images then 
exported to NeurolucidaTM Explorer II (MBF Bioscience, USA). Branched structure analysis was used to analyse 
the number, area and length of primary, secondary, tertiary and quaternary order neurite processes, encompass-
ing both axons and dendrites, of CR-labelled neurons.
Ǥ Neuronal density was analysed using a two-way analysis of variance followed by 
Bonferroni post hoc tests (GraphPad Prism, Version 6.0) for group and regional comparisons. Overall group 
differences (main effects of genotype) were identified using non-parametric two-tailed t-tests. To assess neuronal 
densities across the disease course, three-way analysis of variance was used for comparisons of group and cortical 
regions between different time points (SPSS, Version 20). All variables were tested for statistical interaction, with 
any significant interactions included in the model. Statistical significance was set at P < 0.05. Average values were 
expressed as means ± standard error of mean.
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